XML 33 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Selected Balance Sheet Components (Tables)
 3 Months Ended
Mar. 31, 2021
Balance Sheet Related Disclosures [Abstract]  
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheet dates that comprise the total of the same such amounts shown in the condensed consolidated statements of cash flows for all periods presented in accordance with ASU 2016-18 (in thousands):

 

   

March 31, 2021

(unaudited)

     December 31, 2020  
Cash and cash equivalents   $ 58,907     $ 7,143  
Restricted cash included in deposits and other noncurrent assets (see Note 14)     1,700       1,700  
Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows   $     60,607     $       8,843  
Schedule of Prepaid Expenses and Other Current Assets

As of March 31, 2021 and December 31, 2020, prepaid expenses and other current assets were comprised of the following (in thousands):

 

   

March 31, 2021

(unaudited)

     December 31, 2020  
Prepaid insurance   $ 1,342     $ 264  
Prepaid vendors, deposits and service agreements     977       646  
Other     8       295  
Total prepaid expenses and other current assets   $      2,327     $     1,205  
Schedule of Deposits and Other Noncurrent Assets

As of March 31, 2021 and December 31, 2020, deposits and other noncurrent assets were comprised of the following (in thousands):

 

   

March 31, 2021

(unaudited)

     December 31, 2020  
Restricted cash and security deposit for the Irvine Lease (Note 14)   $ 1,850     $ 1,850  
Long-term prepaid maintenance contracts     97       118  
Other     88       88  
Total deposits and other noncurrent assets   $ 2,035     $ 2,056  
Schedule of Accrued Expenses and Other Current Liabilities

As of March 31, 2021 and December 31, 2020, accrued expenses and other current liabilities were comprised of the following (in thousands):

 

   

March 31, 2021

(unaudited)

     December 31, 2020  
Accrued compensation (1)   $ 2,452     $ 3,556  
Cash holdback liability (see Note 5)     -       600  
Accrued vendor and other expenses     2,812       1,596  
Total accrued expenses and other current liabilities   $ 5,264     $ 5,752  

 

(1) Includes approximately $0.9 million in severance accrual as of March 31, 2021, in accordance with the severance benefits provided under certain employment and severance benefit agreements, in connection with Oncocyte’s partial reduction in force plan and salary reduction agreements instituted in September 2020 (see Note 14).